Trial · NCT02910843
Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
NCT02910843, Phase 1, Terminated, Swiss Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer. Trials, record NCT02910843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02910843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
- NCT number
- NCT02910843
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 25 participants, actual
- Lead sponsor
- Swiss Cancer Institute
- Conditions
- Rectal Cancer
- Interventions
- Regorafenib, Capecitabine, Radiotherapy, Surgery
- First posted
- 2016-09-22
- Last updated
- 2023-01-10
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose limiting toxicity (DLTs) | up to 4 weeks after the last administration of RCT | In the dose escalation part the dose limiting toxicity (DLTs) is observed during and up to 4 weeks after the last administration of RCT. |
| Primary | Pathological near complete or complete tumor response (npCR or pCR) | up to 2 months after end of treatment | In the dose escalation part the pathological near complete or complete tumor response (npCR or pCR) is specified. |
| Secondary | Quality of the mesorectal excision including details of the circumferential resection margin (CRM)/surface | up to 2 months after end of treatment | Quality of the mesorectal excision including details of the circumferential resection margin (CRM)/surface according to Nagtegaal. |
| Secondary | Sphincter preservation | up to 2 months after end of treatment | Sphincter preservation is defined as preservation of the rectal sphincter or part of it. |
| Secondary | Pathological response | up to 2 months after end of treatment | Dworak tumor regression grading (TRG) system. |
| Secondary | Circumferential resection margin (CRM) status | up to 2 months after end of treatment | Negative (clear) circumferential margins are defined by an invasion front which is at a \> 1mm distance from the lateral resection margin; circumferential resection margins of ≤ 1 mm are considered positive (involved). CRM negative (clear) ≤ 1mm and CRM positive (involved) ≤ 1mm. |
| Secondary | Downstaging of primary tumor and/or lymph nodes (comparison between mrT/N and ypT/N) | up to 2 months after end of treatment | Downstaging of primary tumor and/or lymph nodes (comparison between mrT/N and ypT/N) |
| Secondary | Postoperative complications | within 8 weeks after surgery | Surgical complications within 8 weeks after surgery. A surgical local complication is defined as either: * insufficiency of anastomosis * fistula * severe local infection requiring antibiotics * bladder dysfunction * erectile dysfunction * additional interventions / operation needed (e.g. drainage of hematoma/abscess) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02910843
GET https://conductscience.org/api/trials/v1/NCT02910843/registered